Protective role of ginseng in endometriosis during covid-19
Journal of Ginseng Research · 2023-03 · 47 (2) · 169-172
DOI: 10.1016/j.jgr.2022.08.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ginseng Research, 2023-03. Verfasst von JiHyeon Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Seoul, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korean Society of Ginseng.
Abstract (Originalsprache)
The coronavirus disease 2019 (COVID) pandemic began in December 2019. Many countries have implemented restrictions such as mandatory mask wearing and social distancing. These measures have caused diverse and complex health problems, particularly in women's health, anxiety, and depression. This review examines an alternative approach to the treatment of endometriosis during the COVID pandemic. The efficacy of ginseng with anti-inflammatory activity and ability to relieve or prevent symptoms of endometriosis is discussed and reviewed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Seoul, Republic of Korea.
Förderung
- Korean Society of Ginseng
Zitieren
APA
Song, J., & Lee, Y. (2023). Protective role of ginseng in endometriosis during covid-19. Journal of Ginseng Research, 47(2), 169-172. https://doi.org/10.1016/j.jgr.2022.08.002
Vancouver
Song J, Lee Y. Protective role of ginseng in endometriosis during covid-19. Journal of Ginseng Research. 2023;47(2):169-172. doi:10.1016/j.jgr.2022.08.002
BibTeX
@article{Song2023,
author = {Song, JiHyeon and Lee, YoungJoo},
title = {Protective role of ginseng in endometriosis during covid-19},
journal = {Journal of Ginseng Research},
year = {2023},
volume = {47},
number = {2},
pages = {169--172},
doi = {10.1016/j.jgr.2022.08.002}
}
EUVIMED